Podcasts about BMS

Vaughn Halliday, MSc, CFM, SFP, FMP, PMP, ProFM is Manager of Support Services and Facilities for the Central Bank of Trinidad & Tobago where he is a seasoned management executive with a specialized focus on facilities and project management, underpinned by a fervent commitment to sustainability. Mike Petrusky asks Vaughn why he believes that FM professionals need to lead with purpose, adapt with precision, and invest in people as much as they do in technology. They discuss the constant tension between short-term operational demands and long-term asset stewardship which often leads to deferred maintenance and reactive decision-making and Vaughn shares how the effective use of data from CMMS and BMS platforms is essential for driving strategic outcomes. He says that facility managers should move beyond a maintenance mindset and embrace FM as a strategic enabler of business outcomes by investing in training and credential programs at events like IFMA's World Workplace. The future of FM is already here, with AI, IoT, and smart systems reshaping how assets are managed, so Mike and Vaughn encourage and inspire you to be an Asset Champion in your organization! Connect with Vaughn on LinkedIn: https://www.linkedin.com/in/vaughn-halliday/ Learn more about IFMA: https://www.ifma.org/ Explore Eptura™: https://eptura.com/ Discover free resources and explore past interviews at: https://eptura.com/discover-more/podcasts/asset-champion/ Connect with Mike on LinkedIn: https://www.linkedin.com/in/mikepetrusky/  

Dr. Pedro Barata and Dr. Rana McKay discuss the integration of innovative advances in molecular imaging and therapeutics to personalize treatment for patients with renal cell and urothelial carcinomas. TRANSCRIPT Dr. Pedro Barata: Hello, I'm Dr. Pedro Barata, your guest host of By the Book, a podcast series featuring insightful conversations between authors and editors of the ASCO Educational Book. I'm a medical oncologist at University Hospitals Seidman Cancer Center and an associate professor of medicine at Case Western Reserve University in Cleveland, Ohio. I'm also an associate editor of the ASCO Educational Book. Now, we all know the field of genitourinary cancers (GU) is evolving quite rapidly, and we have new innovations in molecular imaging as well as targeted therapeutics. Today's episode will be exploring novel approaches that are transforming the management of renal cell and urothelial carcinomas and also their potential to offer a more personalized treatment to patients. For that, joining for today's discussion is Dr. Rana McKay, a GU medical oncologist and professor at University of California San Diego. Dr. McKay will discuss her recently published article titled, “Emerging Paradigms in Genitourinary Cancers: Integrating Molecular Imaging, Hypoxia-Inducible Factor-Targeted Therapies, and Antibody-Drug Conjugates in Renal Cell and Urothelial Carcinomas.”  Our full disclosures are available in the transcript of this episode.  And with that, Rana McKay, great to have you on the podcast today. Dr. Rana McKay: Oh, thank you so much, Dr. Barata. It's really wonderful to be here with you. So, thanks for hosting. Dr. Pedro Barata: No, thanks for taking the time, and I'm looking forward to this conversation. And by the way, let me start by saying congrats on a great article in the Educational Book. Really super helpful paper. I'm recommending it to a lot of the residents and fellows at my own institution. I would like to first ask you to kind of give our listeners some context of how novel approaches in the molecular imaging as well as targeted therapeutics are actually changing the way we're managing patients with GU, but specifically with renal cell carcinoma and urothelial carcinoma. So, what are the areas you would call out as like being big areas for innovation in this context, and why are they important? Dr. Rana McKay: Very good question. And I think this is really what this article highlights. It highlights where are we going from an imaging diagnostics standpoint? Where are we going from a therapeutic standpoint? And I think if we have to step back, from the standpoint of diagnostics, we've seen PET imaging really transform diagnostics in prostate cancer with the advent of PSMA PET imaging, and now PSMA PET imaging is used as a biomarker for selection for theranostics therapy. And so, we're starting to see that enter into the RCC landscape, enter into the urothelial cancer landscape to a lesser extent. And I think it's going to potentially be transformative as these tools get more refined. I think when we think about therapeutics, what's been transformative most recently in the renal cell carcinoma landscape has been the advent of HIF2α inhibition to improve outcomes for patients. And we have seen the approval of belzutifan most recently that has reshaped the landscape. And now there's other HIF2α inhibitors that are being developed that are going to be further important as they get refined. And lastly, I think when we think about urothelial carcinoma, the greatest transformation to treatment in that context has been the displacement of cisplatin and platinum-based chemotherapy as a frontline standard with the combination of enfortumab vedotin plus pembrolizumab. And we've seen antibody-drug conjugates really reshape treatment and tremendously improve outcomes for patients. So, I think those are the three key areas of interest. Dr. Pedro Barata: So with that, let's focus first on the imaging and then we'll get to the therapeutic area. So, we know there's been a paradigm shift, really, when prostate-specific targets emerged as tracers for PET scanning. And so, we now commonly use prostate-specific membrane antigen, or PSMA-based PET scanning, and really transform how we manage prostate cancer. Now, it appears that we're kind of seeing a similar wave in renal cell carcinoma with the new radiotracer against the target carbonic anhydrase IX. What can you tell us about this? And is this going to be available to us anytime soon? And how do you think that might potentially change the way we're managing patients with RCC today? Dr. Rana McKay: First, I'll step back and say that in the context of PSMA PET imaging, we have actually been able to better understand RCC as well. So, we know that PSMA is expressed in the neovasculature of tumors, and it can actually be used to detect renal cell carcinoma tumors. It has a detection rate of about 84% when used for detection. And so, you know, I don't think it's just restricted to carbonic anhydrase IX, but we will talk about that. So, PSMA expressed in the neovasculature has a detection rate of around 84%, particularly if we're looking at clear cell RCC. CAlX is overexpressed in clear cell RCC, and it's actually used in diagnosing renal cell carcinoma when we think of CAlX IHC for diagnosing clear cell RCC. And now there are CAlX PET tracers. The first foray was with the ZIRCON study that was actually an interestingly designed study because it was designed to detect the likelihood of PET imaging to identify clear cell RCC. So, it was actually used in the early diagnostics setting when somebody presents with a renal mass to discriminate that renal mass from a clear cell versus a non-clear cell, and it was a positive study. But when I think about the potential application for these agents, you know, I think about the entire landscape of renal cell carcinoma. This is a disease that we do treat with metastasis-directed therapy. We have certainly seen patients who've undergone metastasectomy have long, durable remissions from such an approach. And I think if we can detect very early onset oligometastatic disease where a metastasis-directed therapy or SABR could be introduced - obviously tested in a trial to demonstrate its efficacy - I think it could potentially be transformative. Dr. Pedro Barata: Wonderful. It's a great summary, and I should highlight you are involved in some of those ongoing studies testing the performance of this specific PET scanning for RCC against conventional imaging, right? And to remind the listeners, thus far, for the most part, we don't really do FDG-PET for RCC. There are some specific cases we do, but in general, they're not a standard scanning. But maybe that will change in the future. Maybe RCC will have their own PSMA-PET. And to your point, there's also emerging data about the role of PSMA-PET scanning in RCC as well, as you very elegantly summarized. Wonderful. So, let me shift gears a little bit because you did, in your introduction, you did highlight a novel MOA that we have in renal cell carcinoma, approved for use, initially for VHL disease, and after that for sporadic clear cell renal cell carcinoma. We're talking about hypoxia-inducible factor 2-alpha inhibitors, or HIF2α inhibitors, such as belzutifan. But there's also others coming up. So, as a way to kind of summarize that, what can you tell us about this breakthrough in terms of therapeutic class, this MOA that got to our toolbox of options for patients with advanced RCC? Tell us a little bit what is being utilized currently in the management of advanced RCC. And where do you see the future going, as far as, is it moving early on? Is it getting monotherapy versus combinations? Maybe other therapies? What are your thoughts about that? What can you tell us about it? Dr. Rana McKay: Belzutifan is a first-in-class HIF2α inhibitor that really established clinical validation for HIF2α as a therapeutic target. When we think about the activity of this agent, the pivotal LITESPARK-005 trial really led to the approval of belzutifan in patients who were really heavily pretreated. It was patients who had received prior IO therapy, patients who had received prior VEGF-targeted therapy. And in the context of this study, we saw a median PFS of 5.6 months, and there did seem to be a tail on the curve when you looked at the 12-month PFS rate with belzutifan. It was 33.7% compared to 17.6% with everolimus. And then when we look at the response rate, it was higher with belzutifan on the order of 22-23%, and very low with everolimus, as we've previously seen. I think one of the Achilles heels of this regimen is the primary PD rate, which was 34% when used in later line. There are multiple studies that are testing belzutifan in combination across the treatment landscape. So, we have LITESPARK-011, which is looking at the combination of belzutifan plus lenvatinib in the second-line setting. We've got the MK-012 [LITESPARK-012] study, which is looking at belzutifan in various combinations in the frontline setting. So there is a combination with IO plus belzutifan. And so this is also being looked at in that context. And then we also have the LITESPARK-022 study, which is looking at pembrolizumab with belzutifan in the adjuvant setting. So there's a series of studies that will be exploring belzutifan really across the treatment landscape. Many of these studies in combination. Additionally, there are other HIF2α inhibitors that are being developed. We have casdatifan, which is another very potent HIF2α inhibitor. You know, I think pharmacologically, these are different agents. There's a different half-life, different dosing. What is going to be the recommended phase 3 dose for both agents, the EPO suppression levels, the degree of EPO suppression, and sustainability of EPO suppression is very different. So, I think we've seen data from casdatifan from the ARC-20 trial from monotherapy with a respectable response rate, over 30%, primary PD rate hovering just around 10%.  And then we've also seen data of the combination of casdatifan with cabozantinib as well that were recently presented this year. And that agent is also being tested across the spectrum of RCC. It's being looked at in combination with cabozantinib in the PEAK-1 study, and actually just at the KCRS (Kidney Cancer Research Summit), we saw the unveiling of the eVOLVE-RCC trial, which is going to be looking at a volrustomig, which is a PD-1/CTLA-4 inhibitor plus casdatifan compared to nivo-ipi in the frontline setting.  So, we're going to see some competition in this space of the HIF2α inhibitors. I think when we think of mechanism of action in that these are very potent, not a lot of off-target activity, and they target a driver mutation in the disease. And that driver mutation happens very early in the pathogenesis. These are going to be positioned much earlier in the treatment landscape. Dr. Pedro Barata: All these studies, as you're saying, look really promising. And when we talk about them, you mentioned a lot of combinations. And to me, when I think of these agents, it makes a lot of sense to combine because there's not a lot of overlapping toxicities, if you will. But perhaps for some of our listeners, who have not used HIF2α inhibitors in practice yet, and they might be thinking about that, what can you tell us about the safety profile? How do you present it to your patients, and how do you handle things like hypoxia or anemia? How do you walk through the safety profile and tolerability profile of those agents like belzutifan? Dr. Rana McKay: I think these drugs are very different than your traditional TKIs, and they don't cause the classic symptoms that are associated with traditional TKIs that many of us are very familiar with like the rash, hand-foot syndrome, hypertension, diarrhea. And honestly, these are very nuanced symptoms that patients really struggle with the chronicity of being on a chronic daily TKI. The three key side effects that I warn patients about with HIF2α inhibitors are: (1) fatigue; (2) anemia; and (3) hypoxia and dysregulation in the ability to sense oxygen levels. And so, many of these side effects - actually, all of them - are very dose-dependent. They can be very well-managed. So, we can start off with the anemia. I think it's critically important before you even start somebody on belzutifan that you are optimizing their hemoglobin and bone marrow function. Make sure they don't have an underlying iron deficiency anemia. Make sure they don't have B12 or folate deficiency. Check for these parameters. Many patients who have kidney cancer may have some hematuria, other things where there could be some low-level blood loss. So, make sure that those are resolved or you're at least addressing them and supplementing people appropriately. I monitor anemia very closely every 3 to 4 weeks, at least, when people start on these medications. And I do initiate EPO, erythropoietin, should the anemia start to worsen. And I typically use a threshold of around 10g/dL  for implementing utilization of an EPO agent, and that's been done very safely in the context of the early studies and phase 3 studies as well. Now, with regards to the hypoxia, I think it's also important to make sure that you're selecting the appropriate individual for this treatment. People who have underlying COPD, or even those individuals who have just a very high burden of disease in their lung, lymphangitic spread, pleural effusions, maybe they're already on oxygen - that's not an ideal candidate for belzutifan. Something that very easily can be done in the clinic before you think about initiating somebody on this treatment, and has certainly been integrated into some of the trials, is just a 6-minute walk test. You know, have the patient walk around the clinic with one of the MAs, one of the nurses, put the O2 sat on [measuring oxygen saturation], make sure they're doing okay. But these side effects, like I said, are very dose-dependent. Typically, if a patient requires, if the symptoms are severe, the therapy can be discontinued and dose reduced. The standing dose is 120 mg daily, and there's two dose reductions to 80 mg and 40 mg should somebody warrant that dose modification. Dr. Pedro Barata: This is relatively new, right? Like, it was not that we're used to checking oxygen levels, right? In general, we're treating these patients, so I certainly think there's a learning curve there, and some of the points that you highlight are truly critical. And I do share many of those as well in our practice. Since I have you, I want to make sure we touch base on antibody-drug conjugates as well. It's also been a hot area, a lot of developments there. When I think of urothelial carcinoma and renal cell carcinoma, I see it a little bit different. I think perhaps in urothelial carcinoma, antibody-drug conjugates, or ADCs, are somewhat established already. You already mentioned enfortumab vedotin. I might ask you to expand a little bit on that. And then in renal cell carcinoma, we have some ADCs as well that you include in your chapter, and that I would like you to tell us what's coming from that perspective. So, tell us a little bit about how do you see ADCs in general for GU tumors, particularly UC and RCC? Tell us a little bit about the complexity or perhaps the challenges you still see. At the same time, tell us about the successes. Dr. Rana McKay: Stepping back, let's just talk about like the principles and design of ADCs. So, most ADCs have three components. There's a monoclonal antibody that typically targets a cell surface antigen, which is conjugated by a linker, which is the second component, to a payload drug. And typically, that payload drug has been chemotherapy, whether it be topoisomerase or whether it be MMAE or other chemotherapeutic. We can start in the RCC space. There's been multiple antibody-drug conjugates that have been tested. There's antibody-drug conjugates to CD70, which is expressed on clear cell RCC. There's been antibody-drug conjugates to ENPP3, which is also expressed on RCC. There's antibody-drug conjugates to CDH6. And they have different payloads, like I said, whether it be topoisomerase I or other microtubule inhibitors. Now, when we think about kidney cancer, we don't treat this disease with chemotherapy. This disease is treated with immunotherapy. It is treated with treatments that target the VEGF pathway and historically has not been sensitive to chemo. So, I think even though the targets have been very exciting, we've seen very underwhelming data regarding activity, and in some context, seen increased toxicity with the ADCs. So, I think we need to tread lightly in the context of the integration and the testing of ADCs in RCC. We just came back from the KCRS meeting, and there was some very intriguing data about a c-Kit ADC that's being developed for chromophobe RCC, which is, you know, a huge unmet need, these variant tumors that really lack appropriate therapeutics. But I just caution us to tread lightly around how can we optimize the payload to make sure that the tumor that we're treating is actually sensitive to the agent that's targeting the cell kill. So, that's a little bit on the ADCs in RCC. I still think we have a long way to go and still in early testing. Now, ADCs for UC are now the standard of care. I think the prototypical agent, enfortumab vedotin, is a nectin-4-directed ADC that's conjugated to an MMAE payload and was the first ADC approved for advanced urothelial, received accelerated approval following the EV-201 trial, which was basically a multicenter, single-arm study that was investigating EV in cisplatin-ineligible patients with advanced urothelial carcinoma, and then ultimately confirmed in the EV-301 study as well. And so, that study ended up demonstrating the support superiority of EV from an overall survival standpoint, even PFS standpoint. Building on that backbone is the EV-302 study, which tested EV in combination with pembrolizumab versus platinum-based chemotherapy in the frontline setting. And that was a pivotal, landmark study that, like I said, has displaced platinum therapy as a frontline treatment for people with advanced urothelial carcinoma. And when we think about that study and the median overall survival and just how far we've come in urothelial cancer, the median OS with EV-pembro from that trial was 31 and a half months. I mean, that's just incredible. The control arm survival was 16 and a half months. The hazard ratio for OS, 0.47. I mean this is why when this data was presented, it was literally a standing ovation that lasted for several minutes because we just haven't seen data that have looked that good. And there are other antibody-drug conjugates that are being tested. We've all been involved in the saga with sacituzumab govitecan, which is a trophoblast cell surface antigen 2 (Trop-2) targeted ADC with a topoisomerase I payload. It was the second ADC to receive approval, but then that approval was subsequently withdrawn when the confirmatory phase 3 was negative, the TROPiCS-04 trial. So, approval was granted based off of the TROPHY-U-01, single-arm, phase 2 study, demonstrating a response rate of around 28% and a PFS of, you know, about 5 and a half months. But then failure to show any benefit from an OS standpoint. And I think there's a lot of controversy in the field around whether this agent still has a role in advanced urothelial carcinoma. And I think particularly for individuals who do not have molecular targets, like they're not HER2-amplified or have HER2-positivity or FGFR or other things like that. Dr. Pedro Barata: Fantastic summary, Rana. You were talking about the EV, and it came to mind that it might not be over, right, for the number of ADCs we use in clinical practice in the near future. I mean, we've seen very promising data for ADC against the HER2, right, and over-expression. It also can create some challenges, right, in the clinics because we're asking to test for HER2 expression. It's almost like, it's not exactly the same to do it in breast cancer, but it looks one more time that we're a little bit behind the breast cancer field in a lot of angles. And also has vedotin as a payload. Of course, I'm referring to disitamab vedotin, and there's very elegant data described by you in your review chapter as well. And it's going to be very interesting to see how we sequence the different ADCs, to your point as well. So, before we wrap it up, I just want to give you the opportunity to tell us if there's any area that we have not touched, any take-home points you'd like to bring up for our listeners before we call it a day. Dr. Rana McKay: Thank you so much. I have to say, you know, I was so excited at ASCO this year looking at the GU program. It was fantastic to see the progress being made, novel therapeutics that really there's a tremendous excitement about, not just in RCC and in UC, but also in prostate cancer, thinking about the integration of therapies, not just for people with refractory disease that, even though our goal is to improve survival, our likelihood of cure is low, but also thinking about how do we integrate these therapies early in the treatment landscape to enhance cure rates for patients, which is just really spectacular. We're seeing many of these agents move into the perioperative setting or in combination with radiation for localized disease. And then the special symposium on biomarkers, I mean, we've really come a long, long way. And I think that we're going to continue to evolve over the next several years. I'm super excited about where the field is going in the treatment of genitourinary malignancies. Dr. Pedro Barata: Oh, absolutely true. And I would say within the Annual Meeting, we have outstanding Educational Sessions. And just a reminder to the listeners that actually that's where the different teams or topics for the Educational Book chapters come from, from actually the educational sessions from ASCO. And your fantastic chapter is an example of that, right, focusing on advanced GU tumors. So, thank you so much, Rana, for taking the time, sharing your insights with us today on the podcast. It was a fantastic conversation as always. Dr. Rana McKay: My pleasure. Thanks so much for having me, Dr. Barata. Dr. Pedro Barata: Of course.  And thank you to our listeners for your time today. You will find the link to the article discussed today in the transcript of this episode. I also encourage you to check out the 2025 ASCO Educational Book. You'll find an incredible wealth of information there. It's free, available online, and you'll find, hopefully, super, super important information on the key science and issues that are shaping modern oncology, as we've heard from Dr. McKay and many other outstanding authors. So, thank you, everyone, and I hope to see you soon. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:        Dr. Pedro Barata @PBarataMD Dr. Rana McKay @DrRanaMcKay Follow ASCO on social media:        @ASCO on X (formerly Twitter)        ASCO on Bluesky       ASCO on Facebook        ASCO on LinkedIn        Disclosures:     Dr. Pedro Barata: Stock and Other Ownership Interests: Luminate Medical Honoraria: UroToday Consulting or Advisory Role: Bayer, BMS, Pfizer, EMD Serono, Eisai, Caris Life Sciences, AstraZeneca, Exelixis, AVEO, Merck, Ipson, Astellas Medivation, Novartis, Dendreon Speakers' Bureau: AstraZeneca, Merck, Caris Life Sciences, Bayer, Pfizer/Astellas Research Funding (Inst.): Exelixis, Blue Earth, AVEO, Pfizer, Merck  Dr. Rana McKay: Consulting or Advisory Role: Janssen, Novartis, Tempus, Pfizer, Astellas Medivation, Dendreon, Bayer, Sanofi, Vividion, Calithera, Caris Life Sciences, Sorrento Therapeutics, AVEO, Seattle Genetics, Telix, Eli Lilly, Blue Earth Diagnostics, Ambrx, Sumitomo Pharma Oncology, Esiai, NeoMorph, Arcus Biosciences, Daiichi Sankyo, Exelixis, Bristol Myers Squibb, Merck, Astrazeneca, Myovant Research Funding (Inst.): Bayer, Tempus, AstraZeneca, Exelixis, Bristol Myers Squibb, Oncternal Therapeutics, Artera    

Hour 3 of September 8, 2025 Jacob Townsend talks with Phil Vittetoe, of sponsor of the show, The Trophy Shop, about Tennessee's win over ETSU and previewing the game against Georgia. Then, Jacob is joined by Bristol Motor Speedway president Jerry Caldwell about the upcoming fall race weekend, new Goodyear tires for BMS, and more. Then, Jacob talks about some of the other games of the college football weekend. See omnystudio.com/listener for privacy information.

Jacob Townsend is joined by Bristol Motor Speedway president Jerry Caldwell about the upcoming fall race weekend, new Goodyear tires for BMS, and more.See omnystudio.com/listener for privacy information.

 Adam creates a hypnosis session to help a client release suppressed emotions that were linked to their burning mouth syndrome - BMS. This is designed to release emotions linked to words that were never said and so those emotions are suppressed - which means they can be released in this session.

Mathematician Ian Deters returns to the podcast to summarize the results of his computer simulations of a simple model of "free banking," as guided by Bob's instructions. His report has some good news and bad news for Bob.Mentioned in the Episode and Other Links of Interest:The YouTube version of this conversation.This episode's sponsor, ExPatMoneySummit.com.The website of Ian Deters, including contact info. Ian Deters' appearance on the BMS ep. 287 defending the use of infinite sets in higher mathematics.Bob's recent Human Action podcast episode explaining the Rothbardian view of free banking (and the in-built limits to credit expansion).The Selgin-White 1994 JEL article laying out their model of free banking.Bob's QJAE article critical of the Selgin-White approach to free banking.Help support the Bob Murphy Show.

BMS The Vibe IIWelcome to The Vibe, BMS listeners. If you like a little groove in your hip hop or a little hip hop in your groove, then this is for you. This show will showcase pristine lyrical flow over magnetic 4/4 beats wrapped in a melody of horns, pianos, strings, and guitars.This selection of Hip-Hop productions surely reminds us of when music was Music!This segment features: Stetsasonic. The Roots, A Tribe Called Quest, Common, Brassmunk, and others.DJ Rhythm DeePLAYLIST1. TALKING ALL THAT JAZZ/STETSASONIC2. LUCK OF LUCIAN/TRIBE CALLED QUEST3. POLITICS AS USUAL/JAY Z4. PROCEED/ROOTS5. T.R.O.Y/ PETE ROCK & CL SMOOTH6. GOTCHA OPIN/BLACK MOON7. THE LIGHT/COMMON8. LIFTING OFF/TALIB KWELI & HI-TEK9. SUGAR HILL/AZ10. KICK, PUSH/LUPE FIASCO11. LOOSE ENDS/SERGIO MENDEZ12. FLOETIC/FLOETRY13. THE THROWBACK/BRASSMUNK14. BLUESANOVA/TOM BROWNE15. THE LIGHT/COMMON16. THE FROG/SERGIO MENDES17. WHY YOU HATE THE GAME/THE GAME F/NAS

Martha Bueno is a popular advocate for liberty whose parents fled communist Cuba. She is part of Lyn Ulbricht's new organization dedicated to freeing nonviolent offenders suffering from cruel sentencing.Mentioned in the Episode and Other Links of Interest:The YouTube version of this conversation.This episode's sponsor, PersistSEO.com.The homepage for MACS (Mothers Against Cruel Sentencing).Martha Bueno's X profile; the profile for MACS.Lyn Ulbricht's interview on the BMS.Help support the Bob Murphy Show.

 Adam creates a hypnosis session using the rewind technique and staged dissociation to help a client reduce symptoms to burning mouth syndrome (BMS), which the client felt was linked to a reaction of hearing the results of a scan, which turned out to be incorrect. Adam helps them connect the emotions to the same event if things had happened in a different order, breaking the connection with the original point of inception. 

Adam returns for another crossover, this time to discuss Peter Thiel's fascinating conversation with Ross Douthat.Mentioned in the Episode and Other Links of Interest:The YouTube version of this conversation.This episode's sponsor, The Swan Brothers.The Thiel/Douthat interview.BMS ep 421, building a billionaire's bunker.Bob's article explaining the distinction between Hayek's knowledge problem and Mises' calculation problem (of socialism).The HamanNature substack.Help support the Bob Murphy Show.

Tune in as Isabel and Jade analyse the standout moments from EMJ GOLD's guests this season, uncovering the challenges and opportunities shaping today's pharmaceutical industry. From self-advocacy at work and the future of personalised medicine to disease awareness, market access and making your marketing efforts stand out – they explore the season's core themes, all backed by the latest industry data. Watch our featured guest's full episodes: GSK's Dheepa Chari on the evolving sphere of scientific communication Yacin Marzouki on disrupting the traditional omnichannel model BMS' Anita Gandhi on a decade of change in hematology Pfizer's Richard Maughan on the future of access in the UK GSK's Matt Mortimer-Ryan on behaviour-led pharma marketing Chiesi's Shish Patel on COPD, the climate and improving care AbbVie's Dr Daejin Abidoye on community and compassion in cancer care Bayer's Dr Joana Reis on the promise of AI in breast cancer

The spectacle of the Speedway Classic in Bristol this past weekend did not get rave reviews. News 13 Sports Director Chris Womack was there. He gives us his honest opinion. Joey Logano's Spotter, Coleman Pressley, gives his opinion about doming BMS. Todd Gilliland joins the show as he searches for a win to clinch a playoff spot. Tank and Chris chop through the training camp headlines and do some reminiscing. Also, who would you take in a UFC event just for head coaches?

In today's episode I was joined by Nolan Polson, Vice President of Quality Assurance and Product Quality at Iovance Biotherapeutics.I really wanted to speak to Nolan because he's one of the few leaders who's built quality teams at every stage – from biologics at Amgen to radiopharma at Janssen, to launching two first-in-class cell therapies at Juno/Celgene/BMS.Nolan's career path is a great example of what it looks like to carry foundational quality principles into fast-paced, high-growth settings. He talks about his early scientific passion, how he transitioned from R&D to Quality Ops, and the leadership mindset required to scale from clinical to commercial.We talk about the following:How Nolan's scientific roots in chemistry shaped his quality mindsetTransitioning from R&D into Quality Ops and building speed with structureWhat Big Pharma taught him about good science, mature systems, and agency collaborationScaling product quality teams from 2 to 45 during two cell therapy launchesBuilding empowered leadership teams and the traits he looks for when hiringHow AI can help quality teams move toward review-by-exception and proactive oversightThe difference between biologics and cell therapy mindsets in a commercial settingCreating a culture of continuous learning and succession planningLessons from moving across Amgen, J&J, GSK, BMS, and IovanceWhy autologous cell therapy still holds massive curative potentialNolan is a thoughtful, experienced quality leader who blends deep scientific expertise with a calm, strategic leadership approach.Thank you Nolan for sharing your incredible journey.Hope everyone enjoys the show!

Heather and Chris talk about Bubba Wallace's win at the Brickyard, the debate about the playoffs vs full season points and the preview Iowa. Austin Dillion is the guest, talking about the Speedway Classic at BMS. Heather's final thought is on attendance numbers vs track capacity.

In a market flooded with cheap imports and geopolitical risk, one company is standing its ground.Did you know there's only one North American battery management system (BMS) provider at utility scale—despite growing pressure from subsidized Chinese competitors offering systems at zero cost? Michael Worry, CEO of Nuvation Energy, joins Nico to share how his company became that lone provider. But the core of this episode brings a critical warning: what happens when over 80% of the U.S. battery infrastructure is owned or influenced by foreign governments? And how should engineers and lawmakers respond?Michael takes us on a wild entrepreneurial ride: from building EVs before Tesla was cool to deploying robot kegerators at Burning Man. Nuvation's “garage projects” aren't just PR stunts—they're real-world user acceptance test platforms that prove product reliability under extreme conditions.Expect to learn:

The Cincinnati Reds and Atlanta Braves are on their way to Bristol after the splitting the first two games of a four-game series. Why Bristol? Rod Mullins previews the 2025 MLB Speedway Classic, which will feature a record-breaking crowd – more than 85,000 are expected – at Bristol Motor Speedway, which has been remade into a state-of-the-art baseball stadium for a one-night-only game on Saturday. Rod was at BMS on Thursday, and he takes us behind the scenes to get us ready for this most unique sporting event.

Dr. Mindy talks about the Dr. Mindy experiment and the Heat. And then she answers questions about the flesh eating virus, how to put weight on skinny kids, naegleria fowleri, hormone replacement, getting regular BMs, craving sugar all day long, bunions, blood in the stool, Zoloft side-effects on sleep, wandering cyst and more flesh eating viruses. https://www.youtube.com/@TheDrMindyExperimentSee omnystudio.com/listener for privacy information.

Hour 3 of David Crockett Media Day on July 30, 2025 Jacob Townsend talks about the Speedway Classic not having Ronald Acuna Jr. this weekend. Then, he is joined by David Crockett volleyball and track coaches before being joined by ESPN's Marty Smith to talk about SportsCenter 50 States in 50 Days at BMS, seeing baseball there, hosting SportsCenter, and more. See omnystudio.com/listener for privacy information.

Jacob Townsend is joined by ESPN's Marty Smith to talk about SportsCenter 50 States in 50 Days at BMS, seeing baseball there, hosting SportsCenter, and more. See omnystudio.com/listener for privacy information.

Hear Christopher McKim's journey with moderate to severe plaque psoriasis and the latest clinical trial results from dermatologist, Dr. Christine Cornejo. Join this discussion with moderator Archie Franklin as Christopher McKim, a BMS employee living with moderate to severe plaque psoriasis, and Dr. Christine Cornejo, Director and US Medical Engagement Lead for Dermatology and Rheumatology at BMS, offer a patient and physician's perspective on treating plaque psoriasis from the inside. Listen as Chris presents his journey along with Dr. Cornejo addressing effectiveness and safety information with clinical trial results for a prescription oral treatment option. The intent of this episode is to encourage those who have moderate to severe plaque psoriasis to work with their health care provider to find a treatment option that is right for them. This episode is sponsored by Bristol Myers Squibb. For more information view Full Prescribing Information and Medication Guide . ·       (0:00)   Intro to Psoriasis Uncovered and guest welcome to Bristol Myers Squibb employee and patient Christopher McKim and Dr. Christine Cornejo, Director and US Medical Engagement Lead for Dermatology and Rheumatology at Bristol Myers Squibb. ·       (2:15)  Where the journey to finding the right treatment option for Chris and his moderate to severe plaque psoriasis began.  ·       (3:09)   The decision by Chris and his provider to try an oral systemic medication. ·       (3:28)  The effects and impact of an oral systemic treatment for Chris and his plaque psoriasis. ·       (4:09)   Dr. Cornejo addresses efficacy and clinical trials results. ·       (5:58)   Common side effects and safety concerns for the treatment Chris and his health care provider decided to try.   ·       (6:28)   Health considerations patients and providers should discuss prior to using a systemic treatment.    ·       (6:54)   What to do should side effects occur. ·       (7:10)   How Chris feels with clearer skin after making a change in treatment. ·       (8:14)   Indication and Important Safety Information. Key Takeaways: ·       Moderate to severe plaque psoriasis is a systemic disease.    ·       If you're ready to treat from the inside there is a treatment option that may help.   ·       Work with a health care provider to find the right treatment for moderate to severe plaque psoriasis.   ·       Be proactive by taking steps to learn about treatment options including effectiveness, side effects, safety concerns, and what should be discussed with a health care provider before beginning a new treatment for plaque psoriasis.  Guest Bios:   Christopher (Chris) McKim joined BMS in June of 2022. In his current role he is a Regional Marketer for the dermatology division, prior to that he provided support for 9 Therapeutic Area Specialists for the Pacific South District in the GI division.  Prior to joining BMS, Chris worked at Sanofi, J&J, Leo Pharma, and Sun Pharma in various field and home office roles. Chris resides in beautiful San Diego with his family Susan (wife), Morgan 18, Maddy 16, Mason 14 and two Golden Retrievers and enjoys traveling, cooking and anything associated with the ocean (Deep Sea Fishing, S.C.U.B.A. diving, snorkeling, and boogie boarding). Dr. Christine Cornejo joined Bristol Myers Squibb in 2024 as Director, Medical Engagement Lead for Dermatology and Rheumatology. Prior to joining BMS, she practiced dermatology at Brigham and Women's Hospital and Dana-Farber Cancer Institute in Boston, MA, where she specialized in melanoma and high-risk skin cancer management and served as the Director of Confocal Microscopy. She also served as an Instructor at Harvard Medical School and led the Immunology and Infectious Diseases course for 1st year medical students. Resources: Current Oral Systemic Treatments For additional questions about treatment options contact the NPF Patient Navigation Center

Teddy Downey, Executive Editor of The Capitol Forum, sits down with Tahir Amin, co-founder of I-MAK, to discuss the pharmaceutical industry's misuse of the U.S. patent system—and what it costs American patients and taxpayers.They dive into I-MAK's new report, Overpatented, Overpriced, and explore:How drugs like Eliquis and Ozempic are protected by dozens to hundreds of patentsThe role of patent term extensions, follow-on patents, and settlement deals in delaying generic competitionHow companies like Novo Nordisk and BMS generate tens of billions in additional revenue through strategic patentingWhy the Hatch-Waxman Act and USPTO are failing to protect patients and the public interest Full report: https://www.i-mak.org/overpatented/

Host Sean Grady interviews Dr. Surinder Singh, CEO and co-founder of Relyion Energy Inc. Dr. Singh explains how his company is reshaping energy management through AI-driven forecasting, energy management systems (EMS), and battery management systems (BMS). He shares the story behind Relyion's technology, how it extends battery life up to 20 years, and why utility-scale clients, data centers, and commercial operators are turning to their solutions for smarter, more efficient energy usage. Learn how Relyion outperformed traditional forecasting tools by 13x in ERCOT and why now is the right time to adopt these game-changing innovations.Chapters:00:00 – Introduction to Dr. Surinder Singh and Relyion Energy02:13 – The Three Pillars: Forecasting, EMS, and BMS07:25 – Extending Battery Life Beyond 20 Years12:40 – Relyion's Early Use of Recycled EV Batteries16:50 – Transitioning from Product Demonstration to Platform Innovation21:30 – Minimal-Invasive Technology and Deployment Flexibility24:42 – Beating Traditional Forecasting Models: PG&E and ERCOT Case Studies29:58 – The Power of Forecasting + EMS for Grid Efficiency34:22 – Grocery Store Case Study: ROI in Under 3 Years38:09 – EV Charging, Microgrids, and Peak Shaving Optimization41:32 – Battery Agnosticism and Real-Time Adaptation48:40 – Implementation Timeline and Customer Onboarding53:01 – Cloud-Based Forecasting and Edge AI Hardware56:11 – Commercial Growth and Market Expansion59:55 – Relyion's Holistic Approach vs. Siloed Competition1:03:05 – Utility Design and Grid Planning Applications1:05:28 – Gen AI and New Demands on the Grid1:07:20 – How to Connect with Relyion Energy

Hour 3 of July 28, 2025 Jacob Townsend previews the 2025 season for Unicoi County football. Then, he is joined by Bristol Motor Speedway President Jerry Caldwell to preview the Speedway Classic, talk crowd records, who is throwing first pitch, fan zone, possible roof for BMS, and what is next for the speedway? Finally, Jacob is joined by Unicoi County head football coach Drew Rice to talk about the 2025 Blue Devils. See omnystudio.com/listener for privacy information.

Jacob Townsend is joined by Bristol Motor Speedway President Jerry Caldwell to preview the Speedway Classic, talk crowd records, who is throwing first pitch, fan zone, possible roof for BMS, and what is next for the speedway?See omnystudio.com/listener for privacy information.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.George Tidmarsh, a biopharma veteran and adjunct professor at Stanford's medical school, has been appointed as the new head of the FDA's Center for Drug Evaluation and Research (CDER). His extensive industry experience will be valuable in his new government position. Data secrecy among cell and gene therapy developers is hindering progress in the field, causing fragmentation, stalling innovation, and delaying access to treatments. Meanwhile, Sarepta is facing challenges with its elevidys shipments and has lost platform designation for its technology. At the same time, Roche's phase III trial in COPD has failed, impacting the market path for astegolimab. Layoffs are happening at companies like GSK, Sail, and BioNTech. Experts are exploring new ways to overcome barriers in cell therapy production.Data secrecy among cell and gene therapy developers continues to hinder progress and access to treatments. Acadia has introduced a new team and pipeline with ambitious goals. Patients are fighting for access to Brainstorm's ALS drug after promising real-world data. Moderna's withdrawal of its flu vaccine has left combination flu/COVID-19 vaccines in limbo. In other news, Sarepta is facing challenges with its DMD gene therapy, Ultragenyx's gene therapy for Sanfilippo syndrome is rejected by the FDA, GSK's Blenrep loses an adcomm vote, and BMS' anemia drug Reblozyl fails a Phase III trial. The FDA is experiencing layoffs and employee turnover amid an overhaul. Vinay Prasad overruled reviewers on Moderna's COVID-19 shot for kids. Upcoming events include a webinar on AI for real-world research and job opportunities in the biopharma industry. Readers are encouraged to provide feedback and suggest topics for future coverage.

Adam Haman and Bob Murphy interview Jacob Hornberger to get to the bottom of their differing views on libertarianism and immigration.Mentioned in the Episode and Other Links of Interest:The YouTube version of this conversation.BMS ep 416, which was a response to Hornberger's original critique of Adam and Bob. Jacob's response to them.The HamanNature substack.Help support the Bob Murphy Show.

Adam Haman returns to help Bob respond to a common string of objections he recently received, as feedback on a lecture given to the Menger Institute.Mentioned in the Episode and Other Links of Interest:The YouTube version of this conversation.Bob's lecture to the Menger Institute on private law (and defense).Bob's articles on warlords and the mafia.BMS ep 166 on Arrow's Theorem. Adam and Tyrone discuss Arrow.The HamanNature substack.Help support the Bob Murphy Show.

BMS Summer Fling IIIIn this segment of BMS we celebrate summer and all things hot. It's time to look forward to the weeks and months ahead and enjoy the summers of the past. Let's take this ride together, snap open a ‘cold one' and soak up the sun because before you know it - it's gone.This episode features Fresh Prince & DJ Jazzy Jeff, Roy Ayres, Bob Marley, Tom Browne, and many more.PLAYLIST1. SUMMERTIME/FRESH PRINCE & JAZZY JEFF2. SUMMER LADY/NARADA MICHAEL WALDEN3. SUMMER IN THE STREET/CARRIE LUCAS4. MIDNIGHT PEOPLE/PRELAVA PEICHEVA5. ROCK CREEK PARK/BLACKBYRDS6. BACKYARD PARTY/R. KELLY7. SUMMERTIME FEELING/JERMAINE JACKSON8. SUMMER/CHANTAY SAVAGE9. HOT/ROY AYRES10. SUMMERTIME/DOUG E. FRESH11. SHINE/LALAH HATHAWAY12. TOO HOT/LISA STANSFIELD13. EVERYBODY LOVES THE SUNSHINE/TOM BROWNE14. SUMMER MADNESS/KOOL & THE GANG15. LONG HOT SUMMER/STYLE COUNCIL16. SUNSHINE/BLACK SCIENCE ORCHESTRA17. SUN IS SHINING/BOB MARLEY18. SUMMERTIME (INST)/FRESH PRINCE & JAZZY JEFF

On this episode of Bulture podcast:Was Lucille wrong for pawing her wedding ring?BLACK AMERICANS WHAT HAPPENED TO THE ESSENCE FESTIVAL 2025?Black Family Reunions Have Dropped By 47% Since 1997, With The Main Reasons Being The Loss Of Elders And Lingering Unresolved Family ConflictsRyan Coogler's SINNERS just dropped on HBO Max and folks are locked in this weekend.NFL Bans Justin Tucker for 10 Games of Upcoming Season After 16 Women Accuse Him of MisconductMalik Beasley's Barber and Dentist Want Their Money As FBI Digs Into Gambling ClaimsDr. Umar says he's blocking anyone that wishes him a happy Fourth of JulyFormer NBA player Horace Grant explains how child support stole his 17-year NBA pension.Chuck E. Cheese Launches Chuck's Arcade: An Adult Playground with Booze, Games & Nostalgia, because grown-ups need tokens tooConor McGregor Eyes UFC Comeback at the White House in 2026. The former UFC champ says he's ready to fight on the White House lawn after Trump's bold announcementChicago police believe that Mello Buckzz was the intended target in Thursday night's mass shooting. Surveillance footage of the moment a drive-by shooting unfolded outside Mello Buckzz's album release party, leaving 4 people dead and 14 others injured.Funny Marco goes back and forth with one of his BMs and opens up about how he's struggling to be able see their son.Drake allegedly Dissed LeBron, "I saw bro in the Pop Out with them but been D- riding since 'Headlines" - Drake on 'What Did I Miss?' Drake seemingly disses Rick Ross and mentions the time he got punched in the face in Canada on "What Did I Miss?"Halle Bailey Kisses Mystery Man During Yacht Getaway in ItalyLil Rodney Son reacts to DDG setting his late father's photo as his lock screen, saying he won't diss DDG's desd loved ones because it's unnecessaryOutKast's Big Boi Mourns Uncle's Tragic Death After Road Rage Shooting in AtlantaAt least 13 people killed and over 20 children missing from a summer camp in Texas after catastrophic floodsPresident Trump Has now Officially Signed His "Big, Beautiful Bill" Into Law on The 4th Of July.She didn't feel safe going to his house for a movie/chill so he didn't pay for her food Is he right or wrong for inviting her to his place at the first date?Pittsburgh Steelers Score Jalen Ramsey in Major Trade with Miami DolphinsThe WNBA Is Taking Over: Detroit, Cleveland, and Philly Set to Join the League by 2030Diddy's Team Says “He Ain't No Monster” — Claps Back at Bail Denial

This week on The OneCast Pete, Trey, and Ben are joined by the creator of Volta Power Lithium Batteries.  Beau Batten joins the show to talk lithium batteries, the difference in cells, BMS, chargers, and so much more!  We take a deep dive into one of the topics that we receive the most questions on.   Volta Power USA is a US based Lithium Battery company who is providing premium features, in a superior built battery, for affordable prices.  Things like battery heaters that other companies are charging for are STANDARD with Volta Power USA!   For a limited time as a thank you for all of our listeners Volta Power is providing a 15% off discount on any purchase using the code onecast15!  Be sure to check them out and order your batteries today! Follow Volta Power on all of their socials! Volta Power USA on Instagram Volta Power USA on Facebook Volta Power USA YouTube Support those who help to make this possible!   Hobie Eyewear! If you are looking for highly affordable and high quality polarized glasses to keep you safe on the water look no further than Hobie Eyewear!  Use the link to save 15% off your order! Terry Carpenter Licensed NC Realtor at Coldwell Banker Howard Perry and Walston! Terry is available for all your central NC Real Estate, if you are in the market for a home in the Raleigh Area reach out to Terry at carpentert@hpw.com! Deep Dive App!  Download the Deep Dive App today from your phones app store to get the inside track on where to fish, what to throw, weather, wind, water clarity, and so much more!  Deep Dive App helps you catch more fish! Carolina Waters!  Check out Carolina Waters for all your performance fishing gear, casual t shirts, and headwear.  Use the code TheOneCast and Save 20% off your order. OneCast Fishing! Head over to  OneCast Fishing and use the code TheOneCast at checkout to save 10%!  Join the snagless revolution, catch more fish and lose less tackle! Join the conversation and our community where we work to build the culture of anglers helping anglers OneCast at a time head to The OneCast Community on Facebook Head over and follow us on Instagram for behind-the-scenes videos, studio tours, and sneak peaks of what's coming!  The OneCast on Instagram Help us to continue to grow a culture of Anglers helping Anglers OneCast at a time! If you or someone you know is struggling with mental health and is thinking about harming themselves, reach out  (912)270-3726 (800)273-8255 Support these great organizations who are helping those who help keep us safe and free to talk about fishing! Special Operations Bass Anglers Take a Warrior Fishing Inc. FX3 Inc Heroes' Harvest For His Glory Outdoors Hosts Social Media Pete on Instagram Trey on Instagram

This episode covers: Cardiology This Week: A concise summary of recent studies Big data in cardiology Measuring lipids: what clinicians need to know Milestones Host: Perry Elliott Guests: Carlos Aguiar, Karim Lekadir, Kostas Koskinas Want to watch that episode? Go to: https://esc365.escardio.org/event/1808 Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors.  This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English-language always prevails. Declarations of interests: Stephan Achenbach, Nicolle Kraenkel and Karim Lekadir have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Perry Elliott has declared to have potential conflicts of interest to report: consultancies for Pfizer, BMS, Cytokinetics, AstraZeneca, Forbion. Kostas Koskinas has declared to have potential conflicts of interest to report: speaker fees / honoraria from MSD, Daiichi-Sankyo. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Perry Elliott Guest: Karim Lekadir Want to watch that episode? Go to: https://esc365.escardio.org/event/1808?r Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English-language always prevails. Declarations of interests: Stephan Achenbach, Nicolle Kraenkel and Karim Lekadir have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Perry Elliott has declared to have potential conflicts of interest to report: consultancies for Pfizer, BMS, Cytokinetics, AstraZeneca, Forbion. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson."

In this podcast episode, Miguel Regueiro, MD, discusses developing the medical home model for patients with IBD, technological advances for patients in GI and more. •    Intro :58 •    The interview/about Regueiro 1:03 •    Tell us about your family and where you grew up. 1:24 •    How did you get interested in medicine? 2:16 •    Who were your early influences?  4:18 •    What is the medical home? 5:57 •    How did you develop the idea to apply the medical home model to IBD? 7:45 •    Did you get any funding from the payers for this model to keep costs under control for this patient population? 10:57 •    Why hasn't this model become standard of care for patients with complex IBD? 14:13 •    What has worked, and what hasn't worked when it comes to adopting an integrative care medical home model? 18:15 •    Are there themes patients share as to why they wouldn't want to be enrolled in a medical home? 21:28 •    What motivated your change to go from UPMC to become the GI Chief of Cleveland Clinic? 23:09 •    What have you learned in this position at Cleveland Clinic? 25:23 •    Are you spending a lot of time on the business side of care as opposed to the patient side? 26:34 •    How would you recommend that people prepare for having a position like this? 27:34 •    Are you seeing a shift in excitement over taking on leadership roles outside of traditional academics? 30:02 •    With our clinical tool chest changing so rapidly, is there a common theme that you use to guide the strategy of the institute on what to invest in? 35:06 •    What are the challenges that you still see in the ways we are using telehealth? 39:05 •    What are some of the most exciting things you see on the horizon in the realm of IBD management? 40:26 •    Thank you, Miguel 42:55 •    Thanks for listening 45:11 Miguel Regueiro, MD, is the chief of the Digestive Disease Institute at Cleveland Clinic, and professor in the department of medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. We'd love to hear from you! Send your comments/questions to guttalkpodcast@healio.com. Follow us on X @HealioGastro @sameerkberry @umfoodoc. For more from Regueiro, follow @MRegueiroMD on X. Disclosures: Berry and Chey report no relevant financial disclosures. Regueiro reports being on the advisory boards of and consulting for Abavax, Abbvie, Amgen, Biocon, BMS, Boehringer Ingelheim Pharmaceuticals Inc. (BIPI), Celgene, Celltrion, Gilead, Genentech, Johnson and Johnson, Lilly, Merck, Organon, Pfizer, Prometheus, Roche, Salix, Sanofi, Takeda and UBC.

Are you wondering how to: ✓ Control smart buildings with live sensor data visualized inside Matterport or NavVis digital twins? ✓ Use IBM Maximo and SIM-ON together for proactive asset maintenance and streamlined task tracking? ✓ Integrate building automation tools like KNX, NETxAutomation, and SmartThings into one unified platform? Stay tuned! On WGAN-TV Live at 5 (5 PM Poland | 11 AM ET) on Wednesday, 18 June 2025, our guest is: ✓ SIMLAB Founder and CEO Marek Koźlak, PhD Engineering Together, we'll explore how SIMLAB empowers professionals in Construction, Facilities Management, Building Automation and Property Managers to use these SIMLAB tech integrations: 10 Key SIMLAB Tech Integrations 1. Matterport – industry-standard for immersive 3D twins 2. NavVis – alternative laser-based indoor scanning platform 3. IBM Maximo Applications Suite – enterprise asset management powerhouse 4. KNX IoTech – gold standard for smart building automation 5. NETxAutomation – advanced interoperability for BMS 6. FIBARO by Nice Group – plug-and-play smart devices 7. Schneider Electric – intelligent energy and automation systems 8. Smart Home – customizable home automation setups 9. SmartThings – Samsung's connected device ecosystem 10. Homey – flexible IoT hub for residential control What You'll Learn ✓ How to turn your 3D digital twin into a live operations center for real estate, commercial or hospitality spaces ✓ How SIMLAB STAGES helps AEC teams document and compare building progress visually and spatially ✓ How SIMLAB bridges traditional BMS and IoT into a single, real-time, interactive 3D experience ✓ How global companies use SIMLAB to streamline maintenance, reduce costs, and elevate smart property engagement Questions I'll Ask Marek Facilities & Smart Building Use Q: How does SIMLAB SIM-ON unify control and data across platforms like KNX, FIBARO, Schneider, and SmartThings? Q: How does the Matterport + SIM-ON integration with IBM Maximo drive ROI for enterprise clients? For AEC & Construction Teams Q: How does STAGES improve site communication, milestone validation, and error reduction during construction? Q: How do STAGES users compare scans and BIM models to spot discrepancies and plan better? Tech Innovation Ahead Q: What's next for SIMLAB's roadmap with AI, open APIs, and digital twin navigation across multiple platforms? Why This Episode Matters ✓ See how to scale digital twin tech across industries and countries ✓ Understand what makes SIMLAB unique among digital twin providers ✓ Learn how 10 leading technologies work better—together—with SIMLAB Learn More ✓ Watch WGAN-TV Podcast episodes featuring SIMLAB ✓ Read We Get Around Network Forum posts about SIMLAB

This National Blood Week, the team sit down with Anita Gandhi, Vice President, Translational Development, BMS, to explore the last decade of innovation in hematology and what lies ahead for the space. Together, Anita and Jade discuss Anita's route into the pharmaceutical industry, the current unmet needs of patients with blood cancer, what the future of innovation looks like in hematology and what Anita's HBA Rising Star Award means to her a decade on. A little more on EMJ GOLD's guest… Anita is currently the Vice President of Translational Development at BMS, leading not only hematology translational development at the company, but solid tumour, immunology, cardiology and neurology as well. She has over 20 years of industry experience including drug discovery and translational development, and she was the recipient of the HBA Rising Star Award in 2015.

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.The American Medical Association is calling for a Senate probe into RFK Jr. after he removed all 17 members of the CDC's vaccine advisory board. They are also urging an immediate reversal of the HHS Secretary's decision. In other news, FDA leaders promise support for gene therapy as it faces challenges, Novo Nordisk invests over $800 million in discovering oral obesity drugs, and a new company, InVitro Cell Research, focuses on interventions to slow aging and prevent age-related diseases. FDA Commissioner Marty Makary and CBER Director Vinay Prasad published an article outlining the FDA's priorities, including accelerating cures and deploying artificial intelligence quickly. Other news includes Lilly's muscle-preserving treatment pact, Vertex laying off staff after axing a diabetes asset, and Genentech reshuffling in South San Francisco. Recursion cuts workforce by 20%.FDA leaders have pledged support to gene therapy makers as the industry faces challenges in commercialization. Despite huge valuations, gene therapies are struggling to reach the market. Poor communication about the value of groundbreaking treatments is hindering their prospects. Right of first negotiation deals do not always lead to mergers and acquisitions, as found by Jefferies in their analysis of licensing deals. Trilink's new comprehensive IVT kit simplifies the production of mRNAs. In other news, Lilly strikes a $650 million deal for a muscle-preserving treatment, Odyssey ends its quest for Nasdaq, BMS expands its radiopharma presence, and SpliceBio secures $135 million in funding for protein splicing medicines. Novo ups its obesity efforts with an $800 million pact, while Cullinan makes a $700 million deal for autoimmune T cell engager in China.Thank you for listening to Pharma and Biotech Daily.

Grab your FREE Nutrition 101 Guide for Body Composition to build a flexible, evidence-based approach to eating that supports your physique goals without restriction or dogma:https://www.witsandweights.com/free/nutrition-101-guide--The carnivore diet community claims fiber is unnecessary, even harmful. But what does the science actually say?Learn why fiber does far more than "keep you regular," how eliminating it affects everything from muscle building to longevity, and how to make evidence-based decisions about fiber intake for your goals.Main Takeaways:Fiber produces short-chain fatty acids that reduce inflammation and enhance muscle protein synthesisGoing zero-fiber may provide short-term symptom relief but creates long-term health risks (15-30% higher disease rates)The carnivore claims about fiber being "non-essential" ignore massive benefits for satiety, hormones, and gut healthSmart approach: Address root causes of digestive issues rather than eliminating all fiber permanentlyRelated Episode:The Blue Zone Hoax (and Other Diet Myths That Won't Make You Live Longer) | Ep 330Timestamps:0:01 - The fiber war (Carnivore vs. mainstream nutrition) 4:30 - What fiber actually does beyond BMs 5:51 - How fiber affects muscle building and hormone production 8:33 - The carnivore honeymoon period and what happens long-term 11:56 - Gut bacteria changes and health consequences 14:58 - Debunking carnivore claims about fiber 19:53 - 15-30% lower all-cause mortality with higher fiber 21:37 - How to optimize fiber intake 24:56 - The surprising link between gut bacteria and protein synthesis for building muscleSupport the show

Audio roundup of selected biopharma industry content from Scrip over the business week ended 6 June 2025. In this episode: Sanofi's Blueprint buy; AstraZeneca's breast cancer resistance results at ASCO; BMS and BioNTech's big bispecific deal; Kymera's Dupixent in a pill; and Degron's CEO on pipeline and strategy. https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-T5ID4HF465BXFGAH7C6OOSEGTA/ This episode was produced with the help of AI text-to-voice and voice emulation tools. Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in the Pharma and Biotech world.Jefferies predicts an increase in small tuck-in deals in the biotech industry as companies face challenges accessing capital. Companies and industry groups are offering solutions to mitigate the impact of Trump tariffs on rare disease, cell, and gene therapy. Pitchbook suggests a shift towards more sustainable investing in biotech VC firms. Gilead is gearing up to challenge J&J in the $20 billion multiple myeloma CAR-T market. PTP's generative AI is revolutionizing data summaries for biotech QC workflows. Sanofi recently acquired Blueprint for $9.5 billion, while BMS has committed up to $11 billion with Biontech. Lilly has signed a deal worth up to $870 million, and Regeneron is investing nearly $2 billion in a Chinese obesity drug. Merck's CEO is emphasizing diversity in operations following the defeat of an anti-DEI measure. Immuno-oncology drugs Keytruda and Opdivo may face scrutiny in the near future.In other news, Vigil Neuroscience's Trem2 antibody for a rare brain disease failed in a Phase II trial shortly after Sanofi's acquisition of the company. Analysts believe the results were not surprising and should not impact the deal. Lilly has signed a deal worth up to $870 million to develop a long-acting GLP-1 obesity drug, while the FDA is committed to making rare disease drugs available at the first sign of promise. Pharma tuck-in deals are increasing after a slow first quarter for small biotechs. BioAgc Biologics will be attending Bio International in Boston to discuss their global drug production capabilities.Stay tuned for more updates on investing in research, welcoming global talent, the biotech VC cycle, Gilead's challenge to J&J in the multiple myeloma CAR-T market, and much more. Upcoming events and job listings in the pharmaceutical industry are also featured in our newsletter.Thank you for tuning in to Pharma and Biotech daily.

Bob explains the fundamental role that subjective choice plays in various fields, suggesting there is something quite extraordinary about it.Mentioned in the Episode and Other Links of Interest:Bob's book Choice. A recent Human Action podcast episode with Jonathan Newman, discussing Bob's introductory textbook and why action is so important in economic science.BMS ep. 304, the first installment of the Bible commentary, which includes Bob's movie theater analogy for reconciling free will and determinism.BMS ep. 257 laying out Hans Hoppe's case that Mises' action axiom solved the mind-body problem.A good YT video explaining the weird results of the 2-slit experiment.A good YT on Bell's Theorem. Sabin Hossenfelder on Hoofdt and superdeterminism.InFi ep. 22 featuring Michael Fraser, who consults with business leaders that they should view AI as a cauldron, not a crystal ball.Background info on the Axiom of Choice from set theory.Help support the Bob Murphy Show.

Adam Haman returns, this time for a 2fer. First he and Bob discuss the recent SoHo Forum debate on immigration between Dave Smith and Alex Nowrasteh. Then they discuss Michael Malice's recent appearance on Bret Weinstein's DarkHorse podcast to talk about egalitarianism and anarchy.Mentioned in the Episode and Other Links of Interest:The YouTube version of this conversation.The SoHo forum debate, and the Michael Malice interview.BMS ep 194 on Bob's views on immigration under anarchy.Dave Smith on the Human Action podcast laying out his views on immigration vis-a-vis libertarian theory.The HamanNature substack.Help support the Bob Murphy Show.

Dr. Protais Nshogoza is the Rwanda National Coordinator for ECLEA (Equipping Church Leaders -- East Africa). He lived through the Rwandan genocide though many of his friends and family did not. Even as a Christian pastor, Protais struggled with thoughts of revenge until God showed him the power of forgiveness.Mentioned in the Episode and Other Links of Interest:The YouTube version of this interview.Protais' organization in Rwanda. The section of ECLEA's website on Rwanda.BMS ep 392 with Jonathan Menn (who started ECLEA).Help support the Bob Murphy Show.

Terry Hulsey joins Bob for a fascinating discussion of history and political science, with an end to providing a framework for Texas secession that can endure.Mentioned in the Episode and Other Links of Interest:The YouTube version of this interview.The Mises Bookstore entry for TL Hulsey's book.BMS on Arrow's Theorem. BMS on Daniel Miller on the Texas Nationalist Movement.Randy Barnett's critique of Nozick in the Journal of Libertarian Studies.The link for Monetary-Metals.com.Help support the Bob Murphy Show.

As if they had watched the previous crossover, Bret Weinstein and Tucker Carlson discuss many of the same issues (such as the existence of God, the multiverse, the role of evolution) that Adam and Bob covered, but also a new one (human sacrifice). So the duo return for another crossover to react.Mentioned in the Episode and Other Links of Interest:The YouTube version of this conversation.The Bret Weinstein appearance on Tucker Carlson.David Gornoski on the BMS talking about Rene Girard and scapegoats.The Martyr Made series on human sacrifice. The Pete Leeson paper.BMS ep 358 in which Adam and Bob discussed Nick Bostrum and simulation theory.The HamanNature substack.Help support the Bob Murphy Show.

This is a free preview of a paid episode. To hear more, visit davidlat.substack.comWelcome to Original Jurisdiction, the latest legal publication by me, David Lat. You can learn more about Original Jurisdiction by reading its About page, and you can email me at davidlat@substack.com. This is a reader-supported publication; you can subscribe by clicking here.I'm very proud of the guests I've hosted on the Original Jurisdiction podcast, who are some of the most interesting and influential figures in the world of law. But I recently noticed a significant gap in their ranks: I've never hosted the general counsel or chief legal officer of a publicly traded company.To remedy this, I went big: I interviewed Sandra Leung, who recently stepped down as executive vice president and general counsel of Bristol Myers Squibb (BMS), the biopharmaceutical giant that's both a Fortune 100 and S&P 100 company. Sandy worked for BMS for almost 33 years, 18 of them as GC—so she's an expert on the crucial role of in-house counsel, with lots of wise advice for GCs and CLOs. At the same time, as a former GC, she was willing to address hot-button topics that many sitting GCs might steer clear of—such as the Trump administration's executive orders targeting law firms, including how these orders should affect the thinking of GCs when considering which law firms to hire as outside counsel.This interview is also timely because May is Asian American, Native Hawaiian, and Pacific Islander (AANHPI) Heritage Month—and Sandy, a past president of the National Asian Pacific American Bar Association (NAPABA), is a longtime leader in the AANHPI community. In our conversation, we discussed why she has devoted so much of her time and energy over the years to advancing diversity—and why she believes it remains essential for organizations, despite the backlash against DEI.Thanks to Sandy for her time, insight, and many years of service to the legal profession. And congratulations to her on a long and successful tenure as GC.Show Notes:* Sandra Leung bio, NAPABA* Bristol Myers Squibb GC to Retire After 33 years With Drugmaker, by Chris O'Malley for Corporate Counsel/Law.com* Bristol-Myers GC Sandra Leung To Retire After 33 Years, by Christine DeRosa for Law360Prefer reading to listening? For paid subscribers, a transcript of the entire episode appears below.Sponsored by:NexFirm helps Biglaw attorneys become founding partners. To learn more about how NexFirm can help you launch your firm, call 212-292-1000 or email careerdevelopment at nexfirm dot com.

Adam Haman returns to help Bob navigate through yet another Twitter battle, this time on Darwin's theory of evolution vs. simulation theory (i.e. the notion that we are all in a giant simulation). Lots of interesting fodder to make you think.Mentioned in the Episode and Other Links of Interest:The YouTube version of this conversation.Bob's battles after his jab at the Carl Sagan account's tweet.BMS ep 303 featuring Jonathan Bartlett, explaining that standard evolutionary theory uses non-random mutations all the time.BMS ep 358 in which Adam and Bob discussed Nick Bostrum and simulation theory.The HamanNature substack.Help support the Bob Murphy Show.

Hoppin Fort Worth is Located at 2616 Weisenberger on Instagram as @hoppinfwtx Music by Taylor Pace on Instagram as @taylorpacemusic Call in to the morning show and let us tell North Texas about your upcoming event! Email: media@fortworthroots.com Call:817.988.1292 Find all of our sponsors under our "Trusted Sponsors" Tab on our soon to be renovated web site, www.fortworthroots.com Donovan Manufacturing www.donovanmfg.com Night vision, thermals, machine gun rentals, AR-15 parts, classes, and more! Also under the same umbrella get all of your print needs through our friends. Banners, vehicle wraps, business cards, brochures, tshirts, and anything else you might need. Find information on the print shop on Facebook at dillon-press. Also, you can email them at dillon@dillon-press.com Purple Web Consulting www.purplewebconsulting.com Website design and hosting, E-commerce integration, digital strategy and consulting. 817.629.6069 Making modern business tools accessible to the small business owner so that they can compete with the big dogs! Fort Worth Float Company Is your day filled with noise and distractions? Overstimulating sounds and activity? Our daily lives have become overwhelmed with tasks and responsibilities, with very few ways to shut off the world for a brief moment. WELCOME TO FORT WORTH FLOAT COMPANY. They specialize in providing sensory deprivation flotation tanks, providing the ultimate relaxation experience. Offering various pricing and packages, and three different tanks, Fort Worth Float Company meets everyone's floating needs. Hoppin (Fort Worth) Weisenberger St, Fort Worth TX 76107 No more waiting for the bar tender. Simply walk up to the wall of taps, scan your arm band, and enjoy!!! This place charges you by the ounce. A great place to unwind or for your next big event. Find them on Instagram as @hoppinfwtx. Have a Fort Worth Event coming up this week? Call during our recording window and let us share it with the city. 817.988.1292. The Davis Team Look no further than our friends at The Davis Team for all of your property needs. No commitment necessary. If you have questions about property then visit them online : yourdavisteam.com or give them a call 817.755.0504 Galaxy Wilderness Disc Golf Galaxy Wilderness is dedicated to promoting Disc Golf to the masses for its health benefits through outdoor therapy, exercise, and camaraderie. Find them on Facebook as Galaxy Wilderness Disc Golf GalaxyWildernessDG@gmail.com (682) 228-0399 The Body Scrubbery on Instagram @thebodyscrubbery Online at www.thebodyscrubbery.com Phone:925.808.8222 A boutique and unique spa experience. "Don't cheat yourself, treat yourself!!" Luxury foot spa, full body scrubs, infrared heat wraps, massage, bubble tub, mud wraps, facials, couples packages, and small group parties. Eaton Data Solutions We work to have relationships with vendor partners who specialize in different methods of vulnerability detection and management so that we can offer enterprise tools and solutions to small and medium sized companies (SMB's). Find them online www.eatondatasolutions.com Roofing Solutions by Darren Houk! Roofing Solutions can help with all your residential and commercial roofing needs. Roofing Solutions by Darren Houk is locally owned and operated. We are insured and have the experience to carry out most roofing projects. Web Page: https://www.roofingsolutionshouk.com/ Phone : 817-882-6520 McFly's Pub 6104 LTjg Barnett Rd, Fort Worth, TX 76114 · 4.1 mi A BADASS little 1980's/ Back to the Future themed bar with an excellent outdoor patio complete with fire pit and room for your fur baby. Daily drink specials and fun activities almost every day of the week. See whats new at McFly's on their Instagram page @McFlysPub. Tres Amigos Tacos and Tequila tresamigostacosandtequila.com Chef Sandy brings a fresh perspective and culinary expertise to Tres Amigos, continuing the spirit of female led entrepreneurship and the culinary excellence that Chef Paul was known for. 909 W Magnolia Ave, Fort Worth, TX 76104 Cloudland Recording Studio www.cloudlandrecordingstudio.com Cloudland Recording Studio is an analog and digital recording studio located in the heart of Fort Worth, Texas. We are just one mile from downtown and five minutes from the Near Southside entertainment district of Magnolia Avenue. Baez Maintenance Services. www.baezmaintenance.com 817-528-3056 BMS is family owned and operated providing professional commercial cleaning services to establishments throughout DFW.With client satisfaction as a primary goal, high quality maintenance is available as frequently as requested. This includes a 24-hour support system, which guarantees a quick response. Since our beginning in 2017 there has only been one major goal here at BMS; customer satisfaction. 

Adam Haman returns to discuss perhaps the most difficult problem in libertarian legal theory: the treatment of children. The discussion then spills over onto the treatment of animals and even AI.Mentioned in the Episode and Other Links of Interest:The YouTube version of this conversation.BMS 182 which laid out the trust approach.Bob (and Gene Callahan)'s critique of Hans Hoppe's argumentation ethics.The HamanNature substack.Help support the Bob Murphy Show.

Adam Haman and Bob interview Domenic Scarcella (author of Good Neighbor, Bad Citizen) on the events leading up to the Crucifixion of Jesus. The conversation includes Domenic's unorthodox take on Judas.Mentioned in the Episode and Other Links of Interest:The YouTube version of this conversation.Domenic Scarcella's substack.Scarcella's earlier appearance on BMS ep. 310, arguing that Jesus was a good neighbor but bad citizen.The HamanNature substack.Help support the Bob Murphy Show.

Bob covers John 2: 13-25, where Jesus drives out the animals and moneychangers from the temple in Jerusalem at the start of His public ministry.Mentioned in the Episode and Other Links of Interest:RC Sproul on cleansing of the temple. John MacArthur on it.The previous episode in this series, i.e. BMS ep. 374, Installment 8: Turning Water Into Wine.Help support the Bob Murphy Show.